A Brazilian cohort of patients with immuno-mediated chronic inflammatory diseases infected by SARS-CoV-2 (ReumaCoV-Brasil Registry) : protocol for a prospective, observational study

Background: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk of infections, including significant morbidity and high mortality. Considering the potential for unfavorable outcomes of SARS-CoV-2 infection in patients with IMRD, several questions were raised regarding the impact of COVID-19 at the start of the pandemic. Objective: This paper presents the protocol of a study that aims to prospectively evaluate patients with IMRD and a confirmed COVID-19 diagnosis (using criteria provided by the Brazilian Ministry of Health). Methods: The study comprised a prospective, observational cohort (patients with IMRD and COVID-19) and a comparison group (patients with only IMRD), with a follow-up time of 6 months to evaluate differences in health outcomes. The primary outcomes will be changes in IMRD disease activity after SARS-CoV-2 infection at 4 time points: (1) at baseline, (2) within 4-6 weeks after infection, (3) at 3 months after the second assessment (±15 days), and (4) at 6 months (±15 days). The secondary outcomes will be the progression rate to moderate or severe forms of COVID-19, need for intensive care unit admission and mechanical ventilation, death, and therapeutic changes related to IMRD. Two outcomes—pulmonary and thromboembolic events in patients with both IMRD and SARS-CoV-2 infection—are of particular interest and will be monitored with close attention (clinical, laboratory, and function tests as well as imaging). Results: Recruitment opened in May 2020, with 1300 participants recruited from 43 sites as of November 2020. Patient recruitment will conclude by the end of December 2020, with follow-up occurring until April 2021. Data analysis is scheduled to start after all inclusion data have been collected, with an aim to publish a peer-reviewed paper in December 2020. Conclusions: We believe this study will provide clinically relevant data on the general impact of COVID-19 on patients with IMRD

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs

Brazilian consensus on the treatment of fibromyalgia

UNIFESP Ambulatório de FibromialgiaUFPR HC ambulatório de fibromialgiaUNIFESPUNIFESP Setor de reumatismos de partes molesPUC-SP Departamento de MedicinaPUC-Campinas Hospital Universitário Serviço de ReumatologiaSociedade Brasileira de ReumatologiaSanta Casa de Belo Horizonte Ambulatório de Fibromialgia Programa de Residência Médica em ReumatologiaFMUSP HC Serviço de ReumatologiaSanta Casa de Campo Grande Setor de Reumatologia programa de Residência em Clínica MédicaUniversidade Federal de Ciências da Saúde de Porto AlegreUNiSULUniversidade Federal do Espírito Santo Hospital Universitário serviço de ReumatologiaSociedade Brasileira de Clínica MédicaSociedade Brasileira para o Estudo da DorAssociação Brasileira de Medicina Física e ReabilitaçãoUniversidade de São Paulo Faculdade de MedicinaUniversidade Federal FluminenseAcademia Brasileira de Neurologia Departamento de DorEuropean Neurological Society Subcomitê de DorPeripheral Nerve SocietyFMUSP Grupo de MãoSociedade Brasileira de ortopedia e TraumatologiaAxia.Bio farmacoeconomia e pesquisa em saúdeUNIFESP Núcleo de Gestão de PesquisasUNIFESP, Ambulatório de FibromialgiaUNIFESP, Setor de reumatismos de partes molesUNIFESP, Núcleo de Gestão de PesquisasSciEL

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry

Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). Conclusions Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process

Erupção liquenóide: secundária ao uso de adalimumabe?

O adalimumabe é um anticorpo recombinante monoclonal IgG1, completamente humano, que se liga especificamente ao fator de necrose tumoral alfa (TNF-a) e neutraliza sua atividade. Relatamos aqui um caso de erupção liquenóide secundária ao uso de adalimuma-be em uma paciente com artrite reumatóide. O quadro melhorou após a suspensão do adalimumabe, com recidiva à reintrodução do medicamento e nova melhora após a suspensão definitiva deste. Embora a paciente estivesse recebendo, concomitantemente ao adalimumabe, metotrexate, corticosteróides e outras drogas, não houve suspensão ou modificação das medicações, exceto o adalimumabe durante todo o período. A ocorrência de erupção liquenóide com o uso do adalimumabe é um evento não esperado, uma vez que, na imunopatologia do líquen plano, o papel do TNF-a parece ser o de propagador da doença. Desse modo, esperaria-se que drogas anti-TNF-a pudessem ser usadas no tratamento do líquen plano e não que atuassem como indutoras desta condição

Achados ultrassonográficos osteomusculares na paracoccidioidomicose

Resumo A paracoccidioidomicose é uma infecção fúngica endêmica na América do Sul. A infecção geralmente é assintomática e afeta principalmente os tratos respiratórios superior e inferior, com dissociação clínico-radiológica. O envolvimento articular é raro, sem um padrão ou lesão radiológica específica. Apresenta-se um relato de caso de paracoccidioidomicose em que os sintomas iniciais do paciente foram rouquidão e artrite. Depois de um exame de ultrassonografia, foram feitos o diagnóstico diferencial de outras artropatias não infecciosas e a análise do material coletado, que revelou infecção pelo fungo Paracoccidioides brasiliensis

Hansen's disease: descriptions of novel ultrasonographic findings

Sem informação836745746CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ300447/2009-4 ; 471343/2011-0 ; 302205/2012-